16:07 EST Foghorn Therapeutics (FHTX) files $300M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Sets 2025 Strategic Objectives
- Foghorn Therapeutics highlights strategic objectives for 2025
- Foghorn Therapeutics Board Member Resignation Announced
- Foghorn Therapeutics price target lowered to $4 from $9 at Morgan Stanley
- Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright